Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

G. Varuni Kondagunta; Jennifer Bacik; Lawrence Schwartz; Joel Sheinfeld; Dean Bajorin; Jacqueline Vuky; Stephanie Marion; Madhu Mazumdar; George J. Bosl; Robert J. Motzer

doi:10.1023/B:DRUG.0000011794.21608.59

Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

G. Varuni Kondagunta, Jennifer Bacik, Lawrence Schwartz, Joel Sheinfeld, Dean Bajorin, Jacqueline Vuky, Stephanie Marion, Madhu Mazumdar, George J. Bosl, Robert J. Motzer

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m²/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

Original language	English (US)
Pages (from-to)	177-179
Number of pages	3
Journal	Investigational New Drugs
Volume	22
Issue number	2
DOIs	https://doi.org/10.1023/B:DRUG.0000011794.21608.59
State	Published - Apr 2004
Externally published	Yes

Keywords

Cisplatin-refractory
Germ cell tumor
Nonseminoma
Phase II
Temozolomide

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/B:DRUG.0000011794.21608.59

Cite this

@article{d43b8f869048447da6816a8e429e51ed,

title = "Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors",

abstract = "Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.",

keywords = "Cisplatin-refractory, Germ cell tumor, Nonseminoma, Phase II, Temozolomide",

author = "Kondagunta, {G. Varuni} and Jennifer Bacik and Lawrence Schwartz and Joel Sheinfeld and Dean Bajorin and Jacqueline Vuky and Stephanie Marion and Madhu Mazumdar and Bosl, {George J.} and Motzer, {Robert J.}",

note = "Funding Information: Support by Schering-Plough Research Institute, and in part by NIH Grants K24 CA-82431, 5T32-CA-09207-26. Carol Pearce for manuscript review.",

year = "2004",

month = apr,

doi = "10.1023/B:DRUG.0000011794.21608.59",

language = "English (US)",

volume = "22",

pages = "177--179",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

TY - JOUR

T1 - Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

AU - Kondagunta, G. Varuni

AU - Bacik, Jennifer

AU - Schwartz, Lawrence

AU - Sheinfeld, Joel

AU - Bajorin, Dean

AU - Vuky, Jacqueline

AU - Marion, Stephanie

AU - Mazumdar, Madhu

AU - Bosl, George J.

AU - Motzer, Robert J.

N1 - Funding Information: Support by Schering-Plough Research Institute, and in part by NIH Grants K24 CA-82431, 5T32-CA-09207-26. Carol Pearce for manuscript review.

PY - 2004/4

Y1 - 2004/4

N2 - Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

AB - Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m2/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.

KW - Cisplatin-refractory

KW - Germ cell tumor

KW - Nonseminoma

KW - Phase II

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=10744223010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223010&partnerID=8YFLogxK

U2 - 10.1023/B:DRUG.0000011794.21608.59

DO - 10.1023/B:DRUG.0000011794.21608.59

M3 - Article

C2 - 14739666

AN - SCOPUS:10744223010

SN - 0167-6997

VL - 22

SP - 177

EP - 179

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this